Tim Boreham

With underlying earnings growth of 7%, chemist owner and supplier EBOS Group is tapping healthy conditions in the sector.

Backed by Rich Lister Prof Khalil (Charlie) Shahin, Vitura Health is paying $5.9 million for a medical cannabis telehealth provider.

Ahead of next week's merger with Chemist Warehouse, Sigma Healthcare shares are being called out as overvalued by some analysts.

Fresh from FDA approval for its paediatric stem-cell product, Mesoblast is pursuing consent for indications of heart disease and back pain.

A slew of trading updates shows consumers are still making discretionary purchases – but with a keen eye for value.

Natural insecticide developer has won $3 million of US military grants to tackle the problems of mosquito-borne diseases, ticks and bed bugs.

The latest ASX small and microcap health news covering everything from drug and biotech developments to medical devices and medicinal cannabis.

The year is ending with a strong flow of clinical results, with Percheron Therapeutics due to release key trial data tomorrow.

On seemingly modest news, Invion shares have gone on a romp as investors grasp the potential of the undervalued cancer drug developer.

Two new biotech companies – Vitrafy and Renerve – listed today, breaking an eight-month drought of life sciences IPOs on the ASX.